##### 

EXHIBIT 10.1



This agreement is dated July 8, 2002 between ________ (“Purchaser”), and NeoTherapeutics, Inc. (“Company”), whereby the parties agree as follows: 

The Purchaser shall buy and the Company agrees to sell ________shares (“Shares”) of the Company’s Common Stock at a price of $0.17 per share for the total amount of ________. The Shares have been registered on a Form S-3, File No. 333-53108, which registration statement has been declared effective by the Securities and Exchange Commission. The Shares are free of restrictive legends and are free of any resale restrictions. The Company is delivering herewith a prospectus supplement on Form 424 (b)(2) regarding the sale of the Shares prior to funding. 

The Purchaser shall wire the purchase amount to the Company to the account set forth below. 

Company Wire Transfer Instructions: 

Chase Manhattan Bank  
1 Chase Plaza  
New York, NY 10004  
ABA # 021 000 021  
FBO Salomon Smith Barney  
A/C # 066-198038  
For Further Credit to:  
Neotherapeutics, Inc.  
A/C # 561-04051-19-103  
  
The Company shall cause its transfer agent to transmit the Shares electronically to the Purchaser by crediting the account set forth below through the Deposit Withdrawal Agent Commission system. 

Purchaser DWAC Instructions: 

* * *

  


* * *

  


* * *  
  
-1- 

* * *

##### 

AGREED AND ACCEPTED:  
NeoTherapeutics, Inc.  
  
  
By:   
  
* * *  
  
Name:  
Title:  
PURCHASER:  
  
* * *  
  
  
  
By:   
  
* * *  
  
Name:  
Title:  
  
-2- 

* * *

##### 

SCHEDULE 1  
Purchaser Shares Purchase Price  
  
* * *

* * *

* * *  
  
Alpha Capital A.G.

2,941,177 $ 500,000  
  
Stonestreet L.P.

1,764,705 $ 300,000  
  
Excalibur Limited Partnership

882,353 $ 150,000  
  
Cranshire Capital L.P.

882,353 $ 150,000  
  
-3-
